The 3D bioprinting space is certainly beginning to get the attention of investors. There are now several companies with the funding needed to develop techniques which could one day lead to a major breakthrough in regenerative medicine.
Today, Isis Innovation, the University of Oxford’s research commercialisation company, announced that OxSyBio Ltd., a spin-out from the University, has raised £1 million from IP Group plc to develop their proprietary 3D droplet printing technology. Professor Hagan Bayley’s group at the University’s Department of Chemistry are the ones who came up with this approach to 3d bioprinting. They used thousands of tiny droplets, coated with a film that mimics the external membrane of an actual living cell. The team then studded the membranes with protein pores, making them act just like simplified cells.
The droplets, which OxSyBio prints, can transmit electrical pulses, like the ones that are used by living cells, to communicate in the human nervous system.
“We also aim to integrate printed tissue-like materials with living tissues, and to print materials that themselves contain living cells. Our long-term goal is to develop a synthetic-tissue printer that a surgeon can use in the operating theatre. In ten years’ time, the use of pieces of synthetic tissue will be commonplace. The fabrication of complex synthetic organs is a more distant prospect. I am delighted to be working with Isis and IP Group to accelerate the development of our new company, OxSyBio. Our goal is to establish ourselves at the frontline of regenerative medicine,” stated Professor Hagan Bayley.
Regenerative medicine is certainly a field that will garner a lot of investor interest over the coming years, as the prospects of 3D printing organs, patches, and other living tissue increases because of natural technological progress.
Alan Aubrey, Chief Executive Officer of IP Group, said: “Synthetic biology and regenerative medicine will be central to the development of healthcare in the 21st century and IP Group is pleased to support OxSyBio as it seeks to develop products that will help to realize the potential of these exciting and growing areas.”
OxSyBio was formed just last month and is based in London England. You can participate in the discussion about OxSyBio, and their 3D droplet bioprinting technology at 3DPrintBoard.
You May Also Like
State of the Art: Carbon Fiber 3D Printing, Part Five
In the first part of our series on carbon fiber 3D printing, we discussed how the material is used in the larger world of manufacturing. As we’ve learned throughout this...
3DPrinterOS Partnering with MilleBot to Containerize Large-Scale 3D Printing
Thanks to a newly announced partnership between Orlando 3D printing startup MilleBot and 3DPrinterOS, a privately held Silicon Valley company that developed an operating system for advanced digital manufacturing, 3D...
AddUp Partners with ORNL for 3D Printed Metal Tooling
French metal 3D printing group AddUp has entered into a $2.7 million agreement with the U.S. Department of Energy’s Oak Ridge National Laboratory (ORNL) to push laser powder bed fusion (PBF)...
Parameter Optimization for 3D Printing of Continuous Carbon Fiber/Epoxy Composites
In the recently published ‘A Sensitivity Analysis-Based Parameter Optimization Framework for 3D Printing of Continuous Carbon Fiber/Epoxy Composites,’ researchers continue to explore the world of enhanced materials for fabrication of...
View our broad assortment of in house and third party products.